Acute urticaria and severe allergy: cross-border specialty drug access for international patients

Quick orientation

Acute urticaria affects up to 20 percent of the general population at some point during life. Chronic spontaneous urticaria is estimated at 0.5 to 1 percent of the population at any given time. Anaphylaxis affects an estimated 1.6 to 5.1 percent of the US population over a lifetime.

Typical age of onset. Any age. Severe allergy presentations and anaphylaxis can occur at any point in life; chronic urticaria most often presents in adults aged 20 to 40.

Severity tiers. Severity ranges from self-limited hives to chronic disabling urticaria to anaphylaxis requiring emergency epinephrine. Refractory chronic urticaria can substantially impair quality of life and is the target of newer biologics.

Why specialty drugs for Acute urticaria and severe allergy are hard to access internationally

Several recent FDA approvals targeting severe allergy and chronic spontaneous urticaria, including needle-free emergency epinephrine, anti-IgE biologics, and oral kallikrein inhibitors for hereditary angioedema, are not yet registered in many markets outside the US and EU. Patients who depend on these newer formulations face a gap between US clinical availability and local pharmacy supply, particularly in MENA and South Asia where regulatory review can lag US approval by 2 to 5 years.

Treatments approved by the FDA

• Neffy (epinephrine nasal spray) — FDA approval: 2024. Mechanism: Sympathomimetic catecholamine, needle-free intranasal delivery for anaphylaxis. Route: Intranasal. US WAC ballpark: Approximately USD 750 per two-pack. Country pricing: Saudi Arabia · India · Qatar · Lebanon.
• Xolair (omalizumab) — FDA approval: 2003 (chronic urticaria indication 2014). Mechanism: Anti-IgE monoclonal antibody. Route: Subcutaneous injection every 2 to 4 weeks. US WAC ballpark: Approximately USD 3,000 to 5,000 per month.
• Ekterly (sebetralstat) — FDA approval: 2025. Mechanism: Plasma kallikrein inhibitor for hereditary angioedema attacks. Route: Oral on-demand. US WAC ballpark: Approximately USD 35,000 per attack episode. Country pricing: Bahrain.
• Kalbitor (ecallantide) — FDA approval: 2009. Mechanism: Plasma kallikrein inhibitor for acute HAE attacks. Route: Subcutaneous injection. US WAC ballpark: Approximately USD 12,000 per attack. Country pricing: Saudi Arabia · Qatar · Jordan · Oman.

Cross-border pathways used for Acute urticaria and severe allergy

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Personal Import Scheme
• Cross-border Prescription

What your physician needs to know

• Confirm whether the patient has chronic spontaneous urticaria, inducible urticaria, or hereditary angioedema; pathways and drug choices differ.
• Anaphylaxis history, baseline tryptase, total IgE, and prior treatment response inform drug selection.
• For Xolair, document failure of antihistamine optimization (up to 4-fold dose escalation) before initiating biologic therapy.
• Needle-free epinephrine formulations are temperature-sensitive; review storage and emergency-use procedure with the patient.
• Some destination countries require a treating allergist or immunologist to co-sign the international supply request.

Common questions

Is Neffy available outside the United States?

Approval status varies. The FDA approved Neffy in 2024 and the EU followed in 2025. In many MENA, South Asian, and African markets Neffy is not yet registered. Reserve Meds confirms current status by destination.

Can a patient bring an emergency supply across borders?

Personal-import allowances differ by country. Some allow a small emergency supply with a prescription; others require an import permit. We help you confirm before shipment.

Is Xolair appropriate for chronic urticaria?

Xolair is FDA-approved for chronic spontaneous urticaria in patients 12 and older who remain symptomatic despite H1 antihistamines. Your allergist makes the clinical determination.

How quickly can a request be processed?

Acute allergy supply requests are prioritized. Typical timeline from prescription receipt to international shipment is 5 to 10 business days, subject to destination-country import requirements.

Does insurance cover this?

Reserve Meds operates a cash-pay model. We do not bill insurance. Some patients submit our invoice to their local insurer for partial reimbursement; results vary by country.

What about hereditary angioedema-specific options?

Several HAE-specific therapies including on-demand and prophylactic agents are available through our pathway. Ekterly (sebetralstat) is the newest oral on-demand option.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Acute urticaria and severe allergy, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Acute urticaria and severe allergy

Reserved for you.